This blockade was due to ERK1/2 activation and not cAMP intracellular level changes; this study was performed in PC-3, DU 145, and LNCaP prostate cancer cells expressing the CLR/RAMP-2 receptor complex [269]. The gene discussed is DCLK3; the disease is prostate cancer.